New diabetes drug ZT002 begins first human safety tests
NCT ID NCT05491421
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested the safety and tolerability of a new drug called ZT002 in 32 healthy volunteers. Participants received either a single or multiple doses of ZT002 or a placebo by injection. The study aims to see if the drug is safe enough to move into larger trials for type 2 diabetes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ZT002
- What this could lead to
- If successful, this could lead to a new injectable treatment for type 2 diabetes that helps control blood sugar.
- What could go wrong
- This is a very early Phase 1 trial with only 32 healthy participants, so it is not designed to prove effectiveness. The drug may cause side effects or fail in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Q-Pharm Pty Limited
Herston, Queensland, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Can a spice and a mindset shift ease diabetic nerve pain?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Could a peptide injection help rebuild Insulin-Making cells?
- A pill for diabetes? new oral drug aims to rival injections